2028, Food and Drug Administration, Patients and Physicians

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2028

Food and Drug Administration

Patients

Physicians

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration

Food and Drug Administration FDA Sales Physicians

A history of blood cancer treatment

pharmaphorum

SEPTEMBER 13, 2022

Over the past two centuries, researchers have identified more than 100 different types of blood cancer, while most patients may be familiar with the big three (leukaemia, lymphoma, and melanoma). In 39-year-old patient Sarah Newbury, Solly observed the appearance of fatigue and bone pain resulting from multiple fractures.

Food and Drug Administration

Food and Drug Administration Patients Engineering Physicians

Pharma Rep Focus

An increasing impact of BCMA-targeting biologics in multiple myeloma

A history of blood cancer treatment

Stay Connected